217 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
Rank Status Study
21 Recruiting Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Conditions: Leukemia;   Leukemia, Myeloid;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Philadelphia Chromosome;   Bone Marrow Diseases;   Hematologic Diseases
Interventions: Drug: Imatinib;   Drug: Radotinib
22 Recruiting Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Condition: Chronic Myeloid Leukemia
Interventions: Drug: mesylate imatinib capsule;   Drug: Glivec
23 Recruiting Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
24 Not yet recruiting Selective T Cell Depletion in Preventing Graft-Versus-Host Disease in Patients With Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, or Chronic Myelogenous Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Graft Versus Host Disease;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Relapsing Chronic Myelogenous Leukemia
Interventions: Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: thiotepa;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: tacrolimus;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
25 Recruiting Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia
Interventions: Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Procedure: umbilical cord blood transplantation;   Procedure: double-unit umbilical cord blood transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
26 Recruiting De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Interventions: Drug: Imatinib;   Drug: nilotinib;   Drug: dasatinib
27 Recruiting Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: PEG-IFN-a2b
28 Recruiting Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib, Pegylated interferon alpha-2b, Imatinib
29 Recruiting Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib stop
30 Recruiting Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Peginterferon α2b;   Drug: Nilotinib
31 Recruiting Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
32 Recruiting A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Nivolumab
33 Unknown  Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Conditions: Myelodysplastic Syndrome;   Myelofibrosis;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Luitpold Azacitidine;   Drug: Vidaza®
34 Recruiting Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)
Condition: Chronic Myeloid Leukemia or Ph Positive ALL
Intervention:
35 Recruiting Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Biological: WT1-sensitized T cells;   Biological: aldesleukin;   Other: laboratory biomarker analysis
36 Recruiting Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
37 Recruiting This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
38 Recruiting Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Zileuton (Zyflo®)  Dasatinib (Sprycel®);   Drug: Dosing with Zileuton/Dasatinib in CML;   Drug: Daily dosing of Zileuton/Dasatinib;   Drug: Daily dosing with Zileuton/Dasatinib for CML
39 Recruiting Telemonitoring Study - for Chronic Myeloid Leukemia (CML)
Condition: Chronic Myeloid Leukemia
Interventions: Behavioral: no access to eMedonline;   Behavioral: eMedonline access
40 Unknown  Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years